Shirley Xue LI

Dr Li is jointly appointed by the Department of Medicine, School of Clinical Medicine, and the Department of Pharmacology and Pharmacy at HKU. Before joining HKU, she obtained Master of Medicine at Peking Union Medical College, Tsinghua University and a PhD in Public Health at the Chinese University of Hong Kong.

Dr Li’s primary research interests lie in health technology assessment (HTA), health economics and real-world outcome (HEOR) research using decision analytic models and routine health records. Dr Li has expertise in healthcare data analytics, cost-effectiveness modelling and health policy evaluation. Since joining HKU, Dr Li has led and contributed to many HEOR projects, all of which involves dynamic interactions with local and international academic collaorators, local government, industry partners, NGOs and other key opinion leaders.

Dr Li’s recent research focuses on biologics utilization and safety, the regional economic burden, the cost-effective solutions for autoimmune diseases, and the development of outcome-based risk-sharing model for innovative and curative therapies. As a core member of CARE Programme (COVID-19 Vaccines Adverse Events Response and Evaluation Programme, https://www.hkcare.hku.hk/ ), Dr Li has led and contributed to several territory-wide, population-based vaccine safety assessement, particulary for patients with immunological conditions. Dr Li also acts as a co-investigator of AI and Pharmaceuticals in Non-Communicable Diseases (Program 4) at the Laboratory of Data Discovery for Health (D²4H, https://www.d24h.hk ).

Dr Li’s research work has been supported by RGC/Early Career Scheme (PI), RGC Collaborative Research Fund (co-PI), Health and Medical Research Fund of the Food and Health Bureau of Hong Kong SAR Government (PI and co-I), HKU Seed Fund (PI), Pfizer Investigator-Innitiated Research Fund (PI), Janssen Educational Research Fund (PI) and the National Natural Science Foundation of China (co-I). Dr Li has published actively in the field of pharmacoepidemiology, HTA and health policy. She has co-authored more than 100 research articles including top-tier specialty journals in Lancet, JAMA and BMJ families.

Research Profile

• Health technology assessment
• Routine care data and real-world outcome research
• Health service and policy research

Companies

• Assistant Professor The University of Hong Kong (2020)
• Co-investigator Laboratory of Data Discovery for Health (2020)
• 荣誉研究员 香港大学深圳医院 (2019)
• 副研究员 香港大学深圳研究院 (2019)
• Research Assistant Professor 香港大学 (2019 — 2020)
• Postdoctoral Research Fellow 香港大学 (2014 — 2019)
• Honorary Research Associate The Chinese University of Hong Kong (2013 — 2015)
• Research and Project Associate Asia Diabetes Foundation (2013 — 2014)

Education

• Doctor of Philosophy The Chinese University of Hong Kong (2009 — 2013)
• Master of Medicine Peking Union Medical College (2006 — 2009)